NCT03618667View on ClinicalTrials.gov

GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 22, 2018

Primary Completion Date

September 8, 2018

Study Completion Date

April 28, 2022

Conditions
Glioblastoma, AdultEGFR Amplification
Interventions
DRUG

GC1118

GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.

Trial Locations (1)

135710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT03618667 - GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification | Biotech Hunter | Biotech Hunter